Cargando…
Response to pembrolizumab in a heavily treated patient with metastatic ovarian carcinosarcoma
BACKGROUND: Ovarian carcinosarcoma is a rare malignancy associated with a high rate of cancer-related mortality even at early stages. Guidelines for systemic treatment have been difficult to establish because the disease is commonly excluded from prospective clinical trials. Ovarian carcinosarcoma i...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6098839/ https://www.ncbi.nlm.nih.gov/pubmed/30147940 http://dx.doi.org/10.1186/s40661-018-0063-3 |
_version_ | 1783348541192667136 |
---|---|
author | Zibetti Dal Molin, Graziela Abrahão, Carina Meira Coleman, Robert L. Maluf, Fernando Cotait |
author_facet | Zibetti Dal Molin, Graziela Abrahão, Carina Meira Coleman, Robert L. Maluf, Fernando Cotait |
author_sort | Zibetti Dal Molin, Graziela |
collection | PubMed |
description | BACKGROUND: Ovarian carcinosarcoma is a rare malignancy associated with a high rate of cancer-related mortality even at early stages. Guidelines for systemic treatment have been difficult to establish because the disease is commonly excluded from prospective clinical trials. Ovarian carcinosarcoma is usually managed as high-grade epithelial ovarian cancer despite major histologic differences. Owing to the rarity and poor prognosis of ovarian carcinosarcoma, salvage treatments and their efficacy have been poorly described. CASE PRESENTATION: A patient heavily treated for ovarian carcinosarcoma showed an objective response to an immune checkpoint inhibitor, pembrolizumab. Pembrolizumab in this patient appeared to provide tumor control in multifocal metastatic sites. CONCLUSIONS: Pembrolizumab should be evaluated in prospective trials for the treatment of ovarian carcinosarcoma and further work is needed to identify patients most likely to respond to this type of intervention. |
format | Online Article Text |
id | pubmed-6098839 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-60988392018-08-24 Response to pembrolizumab in a heavily treated patient with metastatic ovarian carcinosarcoma Zibetti Dal Molin, Graziela Abrahão, Carina Meira Coleman, Robert L. Maluf, Fernando Cotait Gynecol Oncol Res Pract Case Report BACKGROUND: Ovarian carcinosarcoma is a rare malignancy associated with a high rate of cancer-related mortality even at early stages. Guidelines for systemic treatment have been difficult to establish because the disease is commonly excluded from prospective clinical trials. Ovarian carcinosarcoma is usually managed as high-grade epithelial ovarian cancer despite major histologic differences. Owing to the rarity and poor prognosis of ovarian carcinosarcoma, salvage treatments and their efficacy have been poorly described. CASE PRESENTATION: A patient heavily treated for ovarian carcinosarcoma showed an objective response to an immune checkpoint inhibitor, pembrolizumab. Pembrolizumab in this patient appeared to provide tumor control in multifocal metastatic sites. CONCLUSIONS: Pembrolizumab should be evaluated in prospective trials for the treatment of ovarian carcinosarcoma and further work is needed to identify patients most likely to respond to this type of intervention. BioMed Central 2018-08-18 /pmc/articles/PMC6098839/ /pubmed/30147940 http://dx.doi.org/10.1186/s40661-018-0063-3 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Case Report Zibetti Dal Molin, Graziela Abrahão, Carina Meira Coleman, Robert L. Maluf, Fernando Cotait Response to pembrolizumab in a heavily treated patient with metastatic ovarian carcinosarcoma |
title | Response to pembrolizumab in a heavily treated patient with metastatic ovarian carcinosarcoma |
title_full | Response to pembrolizumab in a heavily treated patient with metastatic ovarian carcinosarcoma |
title_fullStr | Response to pembrolizumab in a heavily treated patient with metastatic ovarian carcinosarcoma |
title_full_unstemmed | Response to pembrolizumab in a heavily treated patient with metastatic ovarian carcinosarcoma |
title_short | Response to pembrolizumab in a heavily treated patient with metastatic ovarian carcinosarcoma |
title_sort | response to pembrolizumab in a heavily treated patient with metastatic ovarian carcinosarcoma |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6098839/ https://www.ncbi.nlm.nih.gov/pubmed/30147940 http://dx.doi.org/10.1186/s40661-018-0063-3 |
work_keys_str_mv | AT zibettidalmolingraziela responsetopembrolizumabinaheavilytreatedpatientwithmetastaticovariancarcinosarcoma AT abrahaocarinameira responsetopembrolizumabinaheavilytreatedpatientwithmetastaticovariancarcinosarcoma AT colemanrobertl responsetopembrolizumabinaheavilytreatedpatientwithmetastaticovariancarcinosarcoma AT maluffernandocotait responsetopembrolizumabinaheavilytreatedpatientwithmetastaticovariancarcinosarcoma |